Next-generation heart bypass grafts to naturally restore cardiovascular function...
Next-generation heart bypass grafts to naturally restore cardiovascular function.
Coronary Artery Disease is caused by narrowing of heart arteries that supply blood, often due to atherosclerosis. Coronary artery bypass grafting (CABG) is the gold standard surgery to treat it, and it commonly involves harvesting...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CPP2021-008438
Nuevo injerto humano vascular descelularizado y re-endoteliz...
93K€
Cerrado
GrownValve
A prosthetic heart valve for adults and children, made from...
4M€
Cerrado
PCI2018-093173
DESARROLLO DE PROTOTIPOS PILOTO PARA UNA NUEVA GENERACION DE...
118K€
Cerrado
TEC2013-46242-C3-2-P
EXTENSION DE LA ACTIVIDAD UTIL DE LOS STENT CARDIOVASCULAR...
61K€
Cerrado
PRE2020-095357
BIOIMPLANTES CARDIACOS DE NUEVA GENERACION BASADOS EN VESICU...
99K€
Cerrado
Duración del proyecto: 24 meses
Fecha Inicio: 2022-11-22
Fecha Fin: 2024-11-30
Líder del proyecto
ASML NETHERLANDS B.V.
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Descripción del proyecto
Coronary Artery Disease is caused by narrowing of heart arteries that supply blood, often due to atherosclerosis. Coronary artery bypass grafting (CABG) is the gold standard surgery to treat it, and it commonly involves harvesting patient’s veins from the legs as grafts. This collection affects patients causing chronic pain and costly complications. It also has a high failure rate with >20% implants occluded after 1 year.
Xeltis has developed a unique restorative vascular graft (XABG) that eliminates the need for vein harvesting. The implant provides a homing structure for cells in which cardiac and vascular tissues can be naturally restored, with the related advantages and benefits for patients and the healthcare system. We have proven our technology in first niche applications, as well as completed pre-clinical studies successfully for XABG. Now, we plan to perform a full clinical validation to obtain a CE mark in Europe and start market deployment and commercial up-scaling.